Sign in
CompletedNo phase

Pneumonia Vaccine Education Intervention Study

Key facts

Who runs it
Geisinger Clinic
Where
Wilkes-Barre, United StatesSee the site
Trial code
Status
Completed
People taking part
141 people enrolled
Started
6 May 2024
Ended
26 Jan 2025
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Pneumococcal Vaccine Education
Record updated
8 July 2025

Who can take part

Age
18 years to 64 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Patients admitted to inpatient Family Medicine service with Type I and II Diabetes
  • Patients who have not been previously vaccinated against pneumonia
  • Patients meeting specific eligibility for Prevnar 20 vaccine: Over age of 65 OR have been diagnosed with any of the following: diabetes, chronic obstructive pulmonary disease, or asthma

Who cannot take part

  • Patients that already received pneumonia vaccination in care history
  • Patients with any active infections
  • Patients allergic to any components of the vaccine
  • Patients with pneumonia inpatient diagnosis at time of recruitment
  • Patients who are in an immunosuppressed status

Where in United States

  • Geisinger South Wilkes-BarreWilkes-Barre, United States

About the trial

What the trial wants to find out

The goal of this interventional clinical trial is to investigate the impact of medicine and pharmacy-led education on patient acceptance rates of Prevnar 20 pneumonia vaccination in patients eligible to receive the vaccine. The education intervention and subsequent option to get the vaccine will be done while the patient is admitted to inpatient care, prior to discharge. The main questions the study aims to answer are:

Read full original descriptionShow less

* Will supplemental education about the Prevnar 20 Pneumococcal vaccine influence patient acceptance rates when given a decision to receive it? * Is there any other statistically relevant qualitative reasoning behind the patient's final decision for accepting or refusing the vaccine?

The 2 groups in the trial

  • ControlNo study treatment, for comparison

    Patients randomized into this arm DO NOT RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.

  • TreatmentTreatment being tested

    Patients randomized into this arm RECEIVE Pneumococcal vaccine education prior to given the option to accept or refuse the vaccine.

    Treatment: Pneumococcal Vaccine Education

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Physician-Pharmacy Collaboration to Increase Patient Acceptance of Pneumococcal Immunization Prior to Inpatient Discharge
Record updated
8 July 2025